Focused on improving chemotherapy, the backbone of oncology treatments today
Intravenous administration also requires daycare hospitalization, which is cumbersome for the patient and is a major cost-driver for these treatments. In many large countries, like China, Brazil and Russia, access to these treatments is problematic as patients have to travel long distances for treatment. Additionally, there are only very few specialized cancer centers, so patients have problems with access and waiting times.
Docetaxel and paclitaxel are commonly used and chemotherapeutics. Each drug is indicated for different tumor types. Both drugs are currently administered intravenously, resulting in a high initial blood concentration which is associated with substantial toxicity, often exacerbated by the required excipients and pre-medications.